Intragastric and intraoesophageal pH monitoring in duodenal ulcerpatients: effect of the new histamine H2-receptor antagonist ramixotidine.
The effect of the new histamine H2-receptor antagonist ramixotidine 750 mg p.o., administered at 22.00 h, on intragastric and intraoesophageal pH monitored from 22.00 h to 08.00 h, was studied in a double-blind cross-over trial in 11 duodenal ulcer patients. Placebo and ramixotidine were given to each patient on 2 consecutive days in a randomized sequence. Three patients were excluded from the intragastric pH analysis as the records on the second study day were technically inadequate. No significant carry-over or sequence effect was noted. Intragastric hydrogen ion activity was significantly lower (p = 0.01) after ramixotidine than after placebo: median (range) 24 (9-100) vs 97 (27-188) mmol/l. The percentage of time with intraoesophageal pH less than 4 was less than 5% in all but three recordings, with a maximum value of 12%, and it was not significantly different after the two treatments.
Molgora
M
M
Cattedra di Patologia Medica III, Università degli Studi di Milano, Italy.
Basilisco
G
G
Bozzani
A
A
Camboni
G
G
Bianchi
P A
PA
D000328:Adult; D004311:Double-Blind Method; D004341:Drug Evaluation; D004381:Duodenal Ulcer / Q000503:physiopathology*; D004947:Esophagus / Q000187:drug effects* / Q000503:physiopathology; D005260:Female; D005745:Gastric Acidity Determination; D005764:Gastroesophageal Reflux / Q000503:physiopathology; D006635:Histamine H2 Antagonists / Q000494:pharmacology*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000494:pharmacology; D013270:Stomach / Q000187:drug effects* / Q000503:physiopathology
D006635:Histamine H2 Antagonists; D009536:Niacinamide; C041784:ramixotidine